Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib
Teruo Inamoto, Haruhito Azuma, Masatoshi Adachi, Yutaka Okayama, Toshiyuki Sunaya, Mototsugu Oya
研究成果: Article › 査読